247 related articles for article (PubMed ID: 34040175)
1. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
Middleton MR; Dean E; Evans TRJ; Shapiro GI; Pollard J; Hendriks BS; Falk M; Diaz-Padilla I; Plummer R
Br J Cancer; 2021 Aug; 125(4):510-519. PubMed ID: 34040175
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Shapiro GI; Wesolowski R; Devoe C; Lord S; Pollard J; Hendriks BS; Falk M; Diaz-Padilla I; Plummer R; Yap TA
Br J Cancer; 2021 Aug; 125(4):520-527. PubMed ID: 34040174
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
Terranova N; Jansen M; Falk M; Hendriks BS
Cancer Chemother Pharmacol; 2021 Feb; 87(2):185-196. PubMed ID: 33145616
[TBL] [Abstract][Full Text] [Related]
4. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Plummer R; Dean E; Arkenau HT; Redfern C; Spira AI; Melear JM; Chung KY; Ferrer-Playan J; Goddemeier T; Locatelli G; Dong J; Fleuranceau-Morel P; Diaz-Padilla I; Shapiro GI
Lung Cancer; 2022 Jan; 163():19-26. PubMed ID: 34894455
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Yap TA; O'Carrigan B; Penney MS; Lim JS; Brown JS; de Miguel Luken MJ; Tunariu N; Perez-Lopez R; Rodrigues DN; Riisnaes R; Figueiredo I; Carreira S; Hare B; McDermott K; Khalique S; Williamson CT; Natrajan R; Pettitt SJ; Lord CJ; Banerji U; Pollard J; Lopez J; de Bono JS
J Clin Oncol; 2020 Sep; 38(27):3195-3204. PubMed ID: 32568634
[TBL] [Abstract][Full Text] [Related]
6. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Pal SK; Frankel PH; Mortazavi A; Milowsky M; Vaishampayan U; Parikh M; Lyou Y; Weng P; Parikh R; Teply B; Dreicer R; Emamekhoo H; Michaelson D; Hoimes C; Zhang T; Srinivas S; Kim WY; Cui Y; Newman E; Lara PN
JAMA Oncol; 2021 Oct; 7(10):1536-1543. PubMed ID: 34436521
[TBL] [Abstract][Full Text] [Related]
7. CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed SR; Lord S; El Badri S; Harman R; Holmes J; Kamzi F; Maughan T; McIntosh D; Mukherjee S; Ooms A; Radhakrishna G; Shaw P; Hawkins MA
Br J Cancer; 2024 Feb; 130(3):467-475. PubMed ID: 38129525
[TBL] [Abstract][Full Text] [Related]
8. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
9. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Konstantinopoulos PA; Cheng SC; Wahner Hendrickson AE; Penson RT; Schumer ST; Doyle LA; Lee EK; Kohn EC; Duska LR; Crispens MA; Olawaiye AB; Winer IS; Barroilhet LM; Fu S; McHale MT; Schilder RJ; Färkkilä A; Chowdhury D; Curtis J; Quinn RS; Bowes B; D'Andrea AD; Shapiro GI; Matulonis UA
Lancet Oncol; 2020 Jul; 21(7):957-968. PubMed ID: 32553118
[TBL] [Abstract][Full Text] [Related]
10. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Kim RD; Alberts SR; Peña C; Genvresse I; Ajavon-Hartmann A; Xia C; Kelly A; Grilley-Olson JE
Br J Cancer; 2018 Feb; 118(4):462-470. PubMed ID: 29348486
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
Thomas A; Redon CE; Sciuto L; Padiernos E; Ji J; Lee MJ; Yuno A; Lee S; Zhang Y; Tran L; Yutzy W; Rajan A; Guha U; Chen H; Hassan R; Alewine CC; Szabo E; Bates SE; Kinders RJ; Steinberg SM; Doroshow JH; Aladjem MI; Trepel JB; Pommier Y
J Clin Oncol; 2018 Jun; 36(16):1594-1602. PubMed ID: 29252124
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
[TBL] [Abstract][Full Text] [Related]
17. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Rajan A; Carter CA; Kelly RJ; Gutierrez M; Kummar S; Szabo E; Yancey MA; Ji J; Mannargudi B; Woo S; Spencer S; Figg WD; Giaccone G
Clin Cancer Res; 2012 Apr; 18(8):2344-51. PubMed ID: 22371451
[TBL] [Abstract][Full Text] [Related]
18. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
19. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Murray Stewart T; Von Hoff D; Fitzgerald M; Marton LJ; Becerra CHR; Boyd TE; Conkling PR; Garbo LE; Jotte RM; Richards DA; Smith DA; Stephenson JJ; Vogelzang NJ; Wu HH; Casero RA
Cancer Chemother Pharmacol; 2021 Jan; 87(1):135-144. PubMed ID: 33215270
[TBL] [Abstract][Full Text] [Related]
20. Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours.
Hanauske AR; Endler C; Graefe T; Fleeth J; von Scheel J; Lüdtke FE; Müller-Hagen S; Depenbrock H; Ohnmacht U; Bolling C
Eur J Cancer; 2008 Nov; 44(16):2444-52. PubMed ID: 18804996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
